)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
Jazz Pharmaceuticals
Jazz Pharmaceuticals (JAZZ) investor relations material
Jazz Pharmaceuticals Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary24 Feb, 2026
Executive summary
Achieved record total revenue of $4.3 billion in 2025, up 5% year-over-year, marking the 21st consecutive year of top-line growth and the highest quarterly revenue ever in Q4 at $1.2 billion, driven by strong execution in rare disease and neuroscience.
Three franchises surpassed $1 billion in annual revenue: rare sleep ($2.0B), rare epilepsy ($1.1B), and rare oncology ($1.1B), with major product launches including Modeyso and Zepzelca.
Expanded portfolio with multiple approvals and launches, including Modeyso, Zepzelca in new indications, and HERIZON-GEA-01 Phase 3 results for zanidatamab.
Strategic acquisitions (Chimerix, GW) and licensing (Saniona) expanded pipeline, financial assets, and neuro-oncology expertise.
Resolved major litigation, notably extending Epidiolex's patent runway into the late 2030s, and completed a CEO transition.
Financial highlights
FY25 total revenues reached $4.3 billion (+5% YoY); Q4 2025 revenues were $1.2 billion (+10% YoY).
Non-GAAP adjusted net income for 2025 was $522 million ($8.38 per share); adjusted EPS was $20.65; GAAP net loss was $(356) million.
Generated $1.4 billion in cash from operations and ended 2025 with $2.4 billion in cash and investments.
Rare sleep franchise generated $2.0 billion in FY25; rare epilepsy $1.1 billion (+9% YoY); rare oncology $1.1 billion (+2% YoY).
Modeyso generated $48 million post-launch; Zepzelca revenue reached $320 million (+15% YoY); Ziihera (zanidatamab) contributed $25 million in BTC sales.
Outlook and guidance
2026 revenue guidance is $4.25–$4.50 billion, with double-digit growth expected in rare oncology and epilepsy, and rare sleep revenue expected at $1.8–$1.9 billion.
Non-GAAP adjusted gross margin guidance is 90–91%; R&D spend to increase, driven by zanidatamab and early-stage programs; SG&A $1.26–$1.32 billion; R&D $725–$775 million.
Effective tax rate guidance: 11.5–13.5%; fully diluted shares outstanding expected at 65–66 million.
Key launches and regulatory milestones expected for zanidatamab (1L GEA) and Modeyso.
Double-digit growth in rare oncology and epilepsy expected to offset modest decline in rare sleep franchise due to generic competition.
Xywav 2026 growth drivers and headwinds
Zanidatamab GEA data impact on mBC trial timelines
Key R&D pipeline investments for 2026 growth
Xywav H2 2026 competitive impact
Zani post-HER2 breast cancer unmet need
Rare disease M&A target criteria
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Jazz Pharmaceuticals earnings date
TD Cowen 46th Annual Health Care Conference3 Mar, 2026
Jazz Pharmaceuticals
Next Jazz Pharmaceuticals earnings date
TD Cowen 46th Annual Health Care Conference3 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing treatments for neurological disorders, sleep medicine, and oncology. The company’s portfolio includes products designed to address rare and complex conditions, particularly in the areas of sleep disorders, epilepsy, and cancer. Jazz Pharmaceuticals engages in research, development, and global distribution of its therapies, working to advance treatment options for patients with unmet medical needs. The company is headquartered in Dublin, Ireland, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage